Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Lexicon files investigational NDA for LX2931 in rheumatoid arthritis

Lexicon Pharmaceuticals, Inc. has announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions.

13 Nov 2007

Brain chemical anandamide work as antidepressant

American and Italian researchers have found that boosting the amounts of a marijuana-like brain transmitter called anandamide produces antidepressant effects in test rats.

6 Nov 2007

Herb rosemary fights free radical damage in the brain

Rosemary not only tastes good in culinary dishes such as Rosemary chicken and lamb, but scientists have now found it is also good for your brain.

31 Oct 2007

Discovery of two genes linked to a disabling form of arthritis called ankylosing spondylitis

An international team of researchers led by a Fred Hutchinson Cancer Research Center geneticist has discovered two genes linked to a disabling form of arthritis called ankylosing spondylitis, a painful and progressive disease in which some or all of the spine's vertebrae fuse together.

22 Oct 2007

Childhood epilepsy research offers new hope for seizure control

Scientists still do not know what causes epileptic seizures, but researchers from Melbourne's Howard Florey Institute are one step closer to solving this puzzle with the help of their newly developed genetically modified epileptic mouse.

18 Oct 2007

Sugars, not proteins make bones tough

Researchers have discovered that the structure of human bones is vastly different than previously believed - findings which will have implications for how some debilitating bone disorders are treated.

17 Oct 2007

Wyeth Pharmaceuticals to acquire Haptogen

Wyeth Pharmaceuticals, a division of Wyeth has announced the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies.

8 Oct 2007

40,000 computers used to tackle bird flu in search for new anti-viral drug discoveries

Last month a collaboration of European and Asian researchers launched a new attack against the deadly bird flu virus, harnessing the combined power of more than 40,000 computers across 45 countries to boost the pace of anti-viral drug discovery.

4 Oct 2007

Isis Pharmaceuticals awarded $1.5 million NIH grant to improve RNAi-based therapeutics

Isis Pharmaceuticals, Inc. has announced that it has been awarded a multi-year Phase 2 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH) for up to $1.5 million to design oligonucleotide drugs that can exploit the RNA interference (RNAi) antisense mechanism for disease treatment.

4 Oct 2007

Loss of TDP-43 gene found to be related to age-related neurological disorders

Researchers at Mayo Clinic in Jacksonville have discovered how loss of a gene can lead to accumulation of toxic proteins in the brain, resulting in a common dementia, and they say this mechanism may be important in a number of age-related neurological disorders.

27 Sep 2007

Adnexus Therapeutics to become a subsidiary of Bristol-Myers Squibb

Bristol-Myers Squibb and Adnexus Therapeutics have announced the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Adnexus Therapeutics, developer of a new therapeutic class of biologics called Adnectins.

25 Sep 2007

Cell growth technology promises more successful drug development

Scientists have developed unique technology to grow stem cells and other tissue in the laboratory in conditions similar to the way they grow in the human body.

20 Sep 2007

Gates Foundation digs down deep for TB

The fight against the global tuberculosis (TB) epidemic has received a huge boost in the form of a $280 million grant from the Bill & Melinda Gates Foundation.

20 Sep 2007

Spinal Muscular Atrophy Foundation and BG Medicine collaborate

The Spinal Muscular Atrophy Foundation and BG Medicine have announced a collaboration to discover plasma biomarkers of drug efficacy for spinal muscular atrophy (SMA), the leading genetic cause of mortality in infants and toddlers.

18 Sep 2007

GlaxoSmithKline to pursue novel antibacterial research program for DOD

GlaxoSmithKline has announced that it has signed an agreement with the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DOD), to identify and develop a new class of antibacterials targeting both Gram negative biothreats and conventional Gram negative hospital pathogens.

18 Sep 2007

New Rensselaer tools speed stem cell research

Engineers at Rensselaer Polytechnic Institute have developed tools to help solve two of the main problems slowing the progress of stem cell research - how to quickly test stem cell response to different drugs or genes, and how to create a large supply of healthy, viable stem cells to study from only a few available cells.

13 Sep 2007

Innovative liquid crystal technology offers promise of new drugs

A partnership between Kent State University, Summa Health System and IC-MedTech Inc. has yielded an innovative liquid crystal technology that offers the promise of new drugs which may more effectively manage cancer and other diseases.

10 Sep 2007

Hamburg to become Europe's hub of drug discovery

Hamburg is on its way to becoming a leading hub of Europe's academic drug discovery, with the northern German city's town hall today announcing the foundation of European ScreeningPort GmbH, a company that will run a state-of-the-art drug discovery service centre.

4 Sep 2007

Animal model for dengue research

A mosquito-borne disease often known as "break-bone fever" has found a new enemy in a unique type of mouse.

28 Aug 2007

Cancer Research Technology begins critical role in new Australian cancer research venture

Cancer Research Technology Ltd (CRT) today announces the start of its key role within an ambitious new Australia-based collaboration, Cancer Therapeutics CRC Pty Ltd (CTx), which commenced operations today.

28 Aug 2007